Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.00
-100.0%
$0.20
$0.00
$2.96
$6K-26.4250 shs5,000 shs
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
$1.54
+1.3%
$1.67
$1.40
$3.74
$50.81M0.01318,987 shs337,529 shs
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$2.32
-7.9%
$2.90
$1.10
$6.01
$45.96M1.63495,042 shs569,458 shs
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$15.53
-1.7%
$15.46
$12.62
$26.99
$49.53M0.641,225 shs3,029 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%-99.95%-99.95%-99.95%-99.97%
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
0.00%-2.53%+1.32%-12.00%-49.34%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
0.00%-12.12%-10.42%-13.43%+24.06%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
0.00%+1.66%+6.41%-8.19%-1.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/AN/AN/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
0.8009 of 5 stars
0.03.00.00.02.03.30.0
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
3.1218 of 5 stars
3.65.00.00.02.80.80.6
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
2.0172 of 5 stars
3.53.00.00.03.30.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00
N/AN/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
0.00
N/AN/AN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
3.20
Buy$28.501,128.45% Upside
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
3.00
Buy$35.50128.66% Upside

Current Analyst Ratings Breakdown

Latest CHHE, VTVT, MAIA, and NRXP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/25/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/19/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
8/13/2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
8/11/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
8/4/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
6/20/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
6/6/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$110K0.06N/AN/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
N/AN/AN/AN/A$0.14 per shareN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/A($1.48) per shareN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$1.02M48.55N/AN/A$4.48 per share3.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
-$410K-$0.02N/AN/AN/AN/AN/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
-$23.25M-$1.38N/AN/AN/AN/A-497.29%-165.42%11/11/2025 (Estimated)
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$25.13M-$2.24N/AN/AN/AN/AN/A-550.94%11/13/2025 (Estimated)
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$18.46M-$3.12N/AN/AN/A-179.75%-55.91%11/11/2025 (Estimated)

Latest CHHE, VTVT, MAIA, and NRXP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/18/2025Q2 2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$0.31-$0.98-$0.67-$0.98N/AN/A
8/12/2025Q2 2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.85-$0.92-$0.07-$0.92N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
N/AN/AN/AN/AN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
N/A
2.19
2.19
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/A
0.11
0.11
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/A
4.98
4.98

Institutional Ownership

CompanyInstitutional Ownership
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/A
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
5.65%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
4.27%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
17.51%

Insider Ownership

CompanyInsider Ownership
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
31.30%
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
32.32%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
19.00%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
1.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
4064.95 million44.62 millionNot Optionable
MAIA Biotechnology, Inc. stock logo
MAIA
MAIA Biotechnology
932.99 million22.33 millionNot Optionable
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
219.81 million16.05 millionOptionable
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
93.19 million3.15 millionNot Optionable

Recent News About These Companies

vTv resumes Phase III oral T1D drug study
vTv Therapeutics initiated with a Buy at H.C. Wainwright
vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year

New MarketBeat Followers Over Time

Media Sentiment Over Time

China Health Industries stock logo

China Health Industries OTCMKTS:CHHE

$0.0001 -0.22 (-99.96%)
As of 08/29/2025 09:57 AM Eastern

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.

MAIA Biotechnology stock logo

MAIA Biotechnology NYSEAMERICAN:MAIA

$1.54 +0.02 (+1.32%)
Closing price 08/29/2025 04:10 PM Eastern
Extended Trading
$1.54 0.00 (0.00%)
As of 08/29/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

NRx Pharmaceuticals stock logo

NRx Pharmaceuticals NASDAQ:NRXP

$2.32 -0.20 (-7.94%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$2.35 +0.03 (+1.08%)
As of 08/29/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

vTv Therapeutics stock logo

vTv Therapeutics NASDAQ:VTVT

$15.52 -0.27 (-1.68%)
Closing price 08/29/2025 03:57 PM Eastern
Extended Trading
$15.52 0.00 (0.00%)
As of 08/29/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.